In 2025, as the independent director of Shenzhen Dongfang Technology Group Co., Ltd. (hereinafter referred to as "the Company"), I, Wang Maoxiang, strictly adhered to the relevant regulations of the China Securities Regulatory Commission and the Company’s "Independent Director System." I actively fulfilled my duties as an independent director, adhered to the independence of my position, and made recommendations on matters related to the Company’s operations. I reviewed relevant materials, participated in management discussions, and focused on the construction of major projects, internal control systems, and the establishment of a sound governance structure. The work situation for 2025 is summarized as follows:
I. Basic Situation of Independent Director Work
- Personal Introduction
I am Wang Maoxiang, a PhD in management, and a researcher at the School of Engineering, Peking University. I previously served as the general manager of Fujian North Pharmaceutical Co., Ltd. and the chairman of Xiamen North Pharmaceutical Technology Co., Ltd. I am currently the first independent director of the Company and a researcher at the School of Engineering, Peking University.
- Explanation of Independence
In accordance with the requirements of the China Securities Regulatory Commission's "Measures for the Administration of Independent Directors of Listed Companies," I conducted a comprehensive self-assessment of my independence. The main aspects of independence are as follows: